Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Tiziana Life Sciences, Ltd. (NASDAQ: TLSA), a biotechnology firm focused on developing innovative immunomodulation therapies, has announced a significant minority investment by its Chief Executive Officer, Ivor Elrifi. On August 6, 2026, Elrifi purchased 321,423 common shares at a price of $1.00 per share, resulting in a total investment value of approximately $321,423. This transaction increases his total holdings in the company to 4,793,684 shares.

Tiziana Life Sciences is currently advancing its lead development candidate, intranasal foralumab, which is a fully human anti-CD3 monoclonal antibody. This drug candidate is being explored for its potential to stimulate T regulatory cells through intranasal administration, representing a novel approach to treating neuroinflammatory and neurodegenerative diseases. The company has initiated clinical trials, including a Phase 2a randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy of foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS). Early results from an open-label Expanded Access Program have shown promising outcomes, with all 14 patients demonstrating either improvement or stability of their condition within six months.

The strategic rationale behind Elrifi's recent share acquisition may reflect his confidence in Tiziana's innovative pipeline and the potential for intranasal foralumab to address unmet medical needs in the field of neurology. As the only fully human anti-CD3 monoclonal antibody currently in clinical development, foralumab's unique delivery method aims to enhance both efficacy and safety compared to traditional intravenous therapies. Tiziana's commitment to developing alternative routes of immunotherapy positions it favorably within the biotechnology sector, which is increasingly focused on personalized and less invasive treatment options.

The biotechnology sector is experiencing robust growth, driven by advancements in drug development technologies and increasing investment in innovative therapies. Tiziana's recent transaction underscores the importance of leadership commitment in fostering investor confidence, particularly in clinical-stage companies navigating the complexities of drug development. As the company continues to progress its clinical trials and expand its pipeline, the implications for both Tiziana and the broader biotechnology market could be significant, particularly if foralumab demonstrates successful outcomes in its ongoing studies.

In summary, Ivor Elrifi's investment in Tiziana Life Sciences not only reflects his personal commitment to the company's mission but also highlights the growing interest in novel therapeutic approaches within the biotechnology sector. As Tiziana advances its clinical programs and seeks to bring innovative treatments to market, it remains well-positioned to capitalize on the evolving landscape of immunotherapy and its applications in addressing critical health challenges.